Form 4: BioCardia Director Stertzer Acquires Shares and Warrants in Private Placement

Director Simon H. Stertzer acquired shares and warrants of BioCardia, Inc. through a private placement on April 23, 2025.

Summary

• On April 23, 2025, Simon H. Stertzer, a director of BioCardia, Inc., acquired shares and warrants through a private placement.
• The transaction involved the purchase of 104,986 shares of common stock at a price of $1.905 per share.
• For each share purchased, Stertzer also received a warrant to purchase one additional share of common stock at an exercise price of $1.905.
• The warrants are exercisable immediately and expire on April 23, 2030.
• Following the transaction, Stertzer directly owns 57,138 shares and indirectly owns 120,365 shares through Windrock Enterprises L.L.C., 59,204 shares through the Stertzer Family Trust, 777 shares through the Stertzer Gamma Trust, and 6,102 shares through Stertzer Holdings LLC.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's participation in the private placement, suggesting confidence in the company. However, the document is primarily a regulatory filing, so the sentiment is not overly strong.

Positives

• Insider participation in a private placement can signal confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. A purchase by a director is generally viewed positively.

Stakeholder Impact

• The transaction could positively impact shareholder sentiment due to insider participation.
• The capital raised through the private placement could benefit the company's operations and growth.

Key Dates

Keywords

BioCardia, BCDA, insider trading, Form 4, Stertzer, private placement, warrants, common stock, director